Beam Therapeutics (MEX:BEAM) Other Stockholders Equity: MXN-0 Mil (As of Mar. 2026)


MEX:BEAM Beam Therapeutics Inc MEX:BEAM
66 GF Score
Price MXN628.46
GF Value MXN519.96
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Beam Therapeutics Other Stockholders Equity?

Beam Therapeutics MEX:BEAM 66 Other Stockholders Equity is MXN-0 Mil as of Mar. 2026. GuruFocus rates MEX:BEAM with a GF Score™ of 66/100 and a GF Value™ of MXN519.96 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Beam Therapeutics's Other Stockholders Equity for the quarter that ended in Mar. 2026 was MXN-0 Mil.

Beam Therapeutics's quarterly Other Stockholders Equity increased from Sep. 2025 (MXN0 Mil) to Dec. 2025 (MXN0 Mil) but then declined from Dec. 2025 (MXN0 Mil) to Mar. 2026 (MXN-0 Mil).

Beam Therapeutics's annual Other Stockholders Equity declined from Dec. 2023 (MXN0 Mil) to Dec. 2024 (MXN0 Mil) but then increased from Dec. 2024 (MXN0 Mil) to Dec. 2025 (MXN0 Mil).

Beam Therapeutics Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Beam Therapeutics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beam Therapeutics Other Stockholders Equity Chart

Beam Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only 0.00 -0.00 0.00 0.00 0.00

Beam Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.00
MEX:BEAM
66GF Score
Beam Therapeutics Inc MEX:BEAM
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beam Therapeutics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of MXN-0 Mil mean?
Beam Therapeutics (MEX:BEAM) has a Other Stockholders Equity of MXN-0 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Beam Therapeutics and its competitors.
Is Beam Therapeutics' Other Stockholders Equity too high?
Beam Therapeutics' current Other Stockholders Equity is MXN-0 Mil. Overall, Beam Therapeutics has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' Other Stockholders Equity compare to ELVN and IDYA?
Beam Therapeutics' Other Stockholders Equity of MXN-0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Beam Therapeutics and its competitors. Beam Therapeutics's current Other Stockholders Equity is MXN-0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (MEX:BEAM) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN519.96, compared to a current price of MXN628.46 — trading 20.9% above its estimated fair value. The current Other Stockholders Equity is MXN-0 Mil. Beam Therapeutics' overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Beam Therapeutics (MEX:BEAM), the current Other Stockholders Equity is MXN-0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beam Therapeutics (MEX:BEAM) Overvalued in 2026?

Based on GuruFocus' analysis, Beam Therapeutics stock appears to be overvalued. The current stock price of MXN628.46 is trading 20.9% above its estimated GF Value™ of MXN519.96. GuruFocus considers Beam Therapeutics to be Modestly Overvalued.

Key valuation signals for MEX:BEAM:

  • Other Stockholders Equity: MXN-0 Mil
  • GF Value™: MXN519.96 vs. price of MXN628.46 (20.9% above fair value)
  • GF Score™: 66/100 with 6 warning signs

No single metric tells the full story. See the MEX:BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beam Therapeutics Business Description

Other Exchanges BEAM:USA
Address 238 Main Street, Cambridge, MA, USA, 02142
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
66GF Score

Get the complete analysis for MEX:BEAM

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN628.46
Price
MXN519.96
GF Value